George Eric Davis - May 2, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
May 2, 2024
Transactions value $
-$19,871
Form type
4
Date filed
5/6/2024, 04:45 PM
Previous filing
Apr 1, 2024
Next filing
May 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $20.7K +301 +0.54% $68.65 56.2K Apr 30, 2024 Direct F1
transaction BMRN Common Stock Options Exercise $117K +1.85K +3.29% $63.10 58K May 2, 2024 Direct F2
transaction BMRN Common Stock Sale -$157K -1.85K -3.19% $85.01 56.2K May 2, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -1.85K -4.33% $0.00 40.9K May 2, 2024 Common Stock 1.85K $63.10 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
F3 The price in column 4 is the weighted average price. The purchase price actually received ranged from $85.00 to $85.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.